Abstract
Ovarian cancer (OC) carries a poor prognosis; however, accumulating molecular data for the major histologic subtypes may lead to subtype-specific treatment paradigms. The present review discusses what is currently understood about the major molecular and histologic subgroups of OC. Areas specifically addressed include hormonal pathways, tumor protein p53 (TP53) and AT rich interactive domain 1A (SWI-like; ARID1A) mutation, and the breast cancer 1/2, early onset (BRCA1/2) mutation/poly (ADP-ribose) polymerase 1 (PARP1), phosphatidylinositol-4,5-bisphosphate 3- kinase, catalytic subunit alpha (PI3KCA)/v-akt murine thymoma viral oncogene homolog 1 (AKT1)/mechanistic target of rapamycin (MTOR), and mitogen-activated protein kinase kinase 1 and 2 (MAP2K1/2) pathways. This molecular characterization only very recently has impacted clinical research efforts to develop targeted therapies for both common and rare OC subtypes. This targeted strategy is illustrated by ongoing low-grade serous, clear-cell, and mucinous subtypeexclusive clinical trials evaluating agents based on common molecular abnormalities among patients (i.e., PARP1 inhibitors for BRCA1/2 mutation-positive OC). This report also reviews the published clinical trial efficacy data for investigational therapies within specific subgroups, and summarizes the currently active clinical trials evaluating these agents (e.g., temsirolimus, sunitinib, TP53 immunotherapy, olaparib, iniparib, veliparib). Available data suggest that histologic profiles and molecular tumor markers are valuable resources for identifying patients who may benefit from these specific agents, and future research should focus on targeting molecules and signaling pathways that are most commonly altered in each subtype.
Keywords: Adenocarcinoma-clear cell, adenocarcinoma-endometrioid, adenocarcinoma-mucinous, catalytic subunit alpha (PI3KCA), cystadenocarcinoma-serous, breast cancer 1, early onset (BRCA1) and breast cancer 2, early onset (BRCA2), ovarian cancer, poly (ADP-ribose) polymerase 1 (PARP1), phosphatidylinositol-4, 5-bisphosphate 3-kinase, TP53.
Current Cancer Drug Targets
Title:Unmet Needs in Ovarian Cancer: Dividing Histologic Subtypes to Exploit Novel Targets and Pathways
Volume: 13 Issue: 6
Author(s): Vijaya Galic, Robert L. Coleman and Thomas J. Herzog
Affiliation:
Keywords: Adenocarcinoma-clear cell, adenocarcinoma-endometrioid, adenocarcinoma-mucinous, catalytic subunit alpha (PI3KCA), cystadenocarcinoma-serous, breast cancer 1, early onset (BRCA1) and breast cancer 2, early onset (BRCA2), ovarian cancer, poly (ADP-ribose) polymerase 1 (PARP1), phosphatidylinositol-4, 5-bisphosphate 3-kinase, TP53.
Abstract: Ovarian cancer (OC) carries a poor prognosis; however, accumulating molecular data for the major histologic subtypes may lead to subtype-specific treatment paradigms. The present review discusses what is currently understood about the major molecular and histologic subgroups of OC. Areas specifically addressed include hormonal pathways, tumor protein p53 (TP53) and AT rich interactive domain 1A (SWI-like; ARID1A) mutation, and the breast cancer 1/2, early onset (BRCA1/2) mutation/poly (ADP-ribose) polymerase 1 (PARP1), phosphatidylinositol-4,5-bisphosphate 3- kinase, catalytic subunit alpha (PI3KCA)/v-akt murine thymoma viral oncogene homolog 1 (AKT1)/mechanistic target of rapamycin (MTOR), and mitogen-activated protein kinase kinase 1 and 2 (MAP2K1/2) pathways. This molecular characterization only very recently has impacted clinical research efforts to develop targeted therapies for both common and rare OC subtypes. This targeted strategy is illustrated by ongoing low-grade serous, clear-cell, and mucinous subtypeexclusive clinical trials evaluating agents based on common molecular abnormalities among patients (i.e., PARP1 inhibitors for BRCA1/2 mutation-positive OC). This report also reviews the published clinical trial efficacy data for investigational therapies within specific subgroups, and summarizes the currently active clinical trials evaluating these agents (e.g., temsirolimus, sunitinib, TP53 immunotherapy, olaparib, iniparib, veliparib). Available data suggest that histologic profiles and molecular tumor markers are valuable resources for identifying patients who may benefit from these specific agents, and future research should focus on targeting molecules and signaling pathways that are most commonly altered in each subtype.
Export Options
About this article
Cite this article as:
Galic Vijaya, Coleman L. Robert and Herzog J. Thomas, Unmet Needs in Ovarian Cancer: Dividing Histologic Subtypes to Exploit Novel Targets and Pathways, Current Cancer Drug Targets 2013; 13 (6) . https://dx.doi.org/10.2174/15680096113139990002
DOI https://dx.doi.org/10.2174/15680096113139990002 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Suppression of TLR Signaling by Targeting TIR domain-Containing Proteins
Current Protein & Peptide Science Anti-Cancer Cytotoxic Effects of Multiwalled Carbon Nanotubes
Current Pharmaceutical Design N-Succinyl Chitosan as Buccal Penetration Enhancer for Delivery of Herbal Agents in Treatment of Oral Mucositis
Current Drug Delivery Mitochondrial Dysfunction and Its Relationship with mTOR Signaling and Oxidative Damage in Autism Spectrum Disorders
Mini-Reviews in Medicinal Chemistry Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease
Medicinal Chemistry Therapeutic and Diagnostic Applications of Nanoparticles
Current Drug Targets Overview of SLC22A and SLCO Families of Drug Uptake Transporters in the Context of Cancer Treatments
Current Drug Metabolism Recent Advances in the Probe Development of Technetium-99m Molecular Imaging Agents
Current Organic Synthesis To Preliminarily Evaluate The Anticancer Activiy of 1,2-di(quinazolin-4- yl)diselane Against MDA-MB-435 Cells in vitro
Letters in Drug Design & Discovery Modulation of Cell Death in Age-Related Diseases
Current Pharmaceutical Design Meet Our Editorial Board Member:
Current Cancer Therapy Reviews Histopathology of Ductal Carcinoma in Situ (DCIS) of the Breast
Current Cancer Therapy Reviews Enrichment of Up-regulated and Down-regulated Gene Clusters Using Gene Ontology, miRNAs and lncRNAs in Colorectal Cancer
Combinatorial Chemistry & High Throughput Screening Cerebral Malaria - A Neurovascular Pathology with Many Riddles Still to be Solved
Current Neurovascular Research Variability of Biological Activities of Limonoids Derived from Plant Sources
Mini-Reviews in Organic Chemistry Strategies for Target-Specific Contrast Agents for Magnetic Resonance Imaging
Current Molecular Imaging (Discontinued) Efficacy and Cardiovascular Safety of Insulins
Current Drug Safety Targeted Tumor Diagnosis and Therapy with Peptide Hormones as Radiopharmaceuticals
Anti-Cancer Agents in Medicinal Chemistry Metal Oxide Nanomaterials in Nanomedicine: Applications in Photodynamic Therapy and Potential Toxicity
Current Topics in Medicinal Chemistry Drug Metabolism and Individualized Medicine
Current Drug Metabolism